Ravulizumab (Ultomiris)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses ravulizumab (Ultomiris) for injection, 10 mg/mL and 100 mg/mL concentrate for solution for IV infusion. Indication: For the treatment of adult patients with anti-acetylcholine receptor antibody–positive generalized myasthenia gravis.